Drug profile · INN
tanezumab
RAYLUMIS
tanezumab (RAYLUMIS) is a beta-nerve growth factor inhibitor.
EMA: refused Nervous system (N02) N02
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tanezumab
- Class
- Nervous system (N02)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
tanezumab (RAYLUMIS) is a beta-nerve growth factor inhibitor.
Key facts
INN tanezumab
Brand RAYLUMIS
Mechanism Beta-nerve growth factor inhibitor
Target Beta-nerve growth factor
Therapeutic class Nervous system (N02)
ATC code N02
Mechanism of action
Beta-nerve growth factor inhibitor
Primary target: Beta-nerve growth factor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | refused | — |
Related & competitor drugs
Frequently asked questions
What is tanezumab?
tanezumab (RAYLUMIS) is a beta-nerve growth factor inhibitor.
What is the brand name for tanezumab?
RAYLUMIS is a marketed brand name for tanezumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.